Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery
NCT02637479 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2025-01-30
Summary
80% of palliative care cancer patients suffer from severe pain. The management of these pain improves the quality of life of these patients. The management of opioid pain refractory to date remains a difficulty for caregivers. Hypophysectomy performed to try to control hormone-dependent neoplasia also help relieve pain associated with lesions secondary cancer. The surgical hypophysialis radio Gamma Knife ® was recently performed on a small number of patients. She would have the advantage of reducing the risk of complications compared to other techniques and achieve similar analgesic effect on diffuse, or mixed nociceptive pain associated with metastases on average in 2 days and would reduce or stop opiates most often responsible for side effects impairing the quality of life. The objective of this clinical trial, multicenter, prospective, randomized controlled is to evaluate the effectiveness of surgical hypophysialis radio for patients in palliative situations with refractory cancer pain in opioid level III. The type of pain "cancer pain" was done in order to optimize the recruitment and homogenization of the study population: patients cared for in palliative care units are mostly patients cancer (70-80%). This study is therefore part of a palliative setting and the results of this test can be extrapolated to other populations of palliative patients with refractory pain.
Conditions
- Any Cancer With Multiple Bone Metastases
Interventions
- DEVICE
-
GammaKnife®
- DEVICE
-
18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)
- DEVICE
-
MRI
Sponsors & Collaborators
-
Assistance Publique Hopitaux De Marseille
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-12-31
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- France
Study Locations
More Related Trials
-
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
NCT00110032 ·Status: TERMINATED ·Phase: PHASE1
-
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
NCT04809584 ·Status: APPROVED_FOR_MARKETING
-
18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery
NCT05174026 ·Status: COMPLETED ·Phase: NA
-
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma
NCT07274397 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer
NCT00956163 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma
NCT02876991 ·Status: UNKNOWN ·Phase: NA
-
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
NCT06791226 ·Status: RECRUITING ·Phase: NA
-
Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)
NCT02022800 ·Status: COMPLETED ·Phase: NA
-
Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC
NCT00697333 ·Status: UNKNOWN ·Phase: PHASE2
-
Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma
NCT02971319 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)
NCT00503178 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
NCT02186678 ·Status: COMPLETED ·Phase: NA
-
18F-Fluorocholine for the Detection of Parathyroid Adenomas
NCT03764007 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172 ·Status: COMPLETED ·Phase: NA
-
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
NCT04173104 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
NCT02104310 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer
NCT00647140 ·Status: TERMINATED ·Phase: PHASE2
-
POSitron Emission Imaging Using 18F-FDOPA in Neurooncology
NCT02631655 ·Status: COMPLETED ·Phase: NA
-
MRI Optimization Study in Stage III NSCLC
NCT02076282 ·Status: UNKNOWN
-
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
NCT02149173 ·Status: TERMINATED ·Phase: NA
-
Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques
NCT02747173 ·Status: TERMINATED
-
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
NCT00707343 ·Status: COMPLETED ·Phase: PHASE1
-
Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy
NCT01663753 ·Status: COMPLETED ·Phase: NA
-
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
NCT02317393 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET
NCT01224873 ·Status: UNKNOWN